#USA #Woburn #HCC Treatment #Sirtex Medical #SIR-Spheres

Sirtex Medical's Breakthrough in Tumor Control with SIR-Spheres

Introduction

In a groundbreaking study, Sirtex Medical, a leader in interventional oncology solutions, has achieved remarkable results with its SIR-Spheres® product in treating hepatocellular carcinoma (HCC). The recently published DOORwaY90 study reveals a staggering 100% local tumor control rate, establishing a new benchmark for Y-90 treatment in patients with unresectable HCC.

Highlights of the Study

Conducted as the first pivotal, prospective, and multicenter clinical trial in the United States, the DOORwaY90 study focused on selective internal radiation therapy (SIRT) using Y-90. The study achieved its primary endpoints, reporting an overall response rate (ORR) of 99% and a complete response (CR) rate of 90%. An independent central review noted that all evaluable patients responded positively to the treatment.

The durability of the responses was particularly notable, with about 75% lasting over six months and a median duration of response recorded at an impressive 295 days. This highlights the potential of SIR-Spheres® to achieve long-lasting tumor responses while maintaining liver function, a critical consideration in HCC treatments.

Safety and Efficacy

Another promising outcome of the DOORwaY90 study was the preservation of liver function, with more than 95% of patients maintaining stable liver conditions over a 12-month follow-up period. This finding underscores the effectiveness of personalized dosimetry, which allows physicians to achieve aggressive tumor responses without compromising hepatic reserve.

Dr. Armeen Mahvash, an interventional radiologist at the MD Anderson Cancer Center and a lead investigator for the study, remarked, “The 12-month results indicate the consistency of response achieved through personalized dosimetry. The high rates of complete response, durability, and liver function preservation observed in this study provide greater confidence for physicians in utilizing radioembolization as a definitive treatment option targeting the liver.”

Market Response and Implications

As a result of these exceptional findings, expectations among medical professionals regarding Y-90 therapy have significantly increased. Matt Schmidt, CEO of Sirtex Medical, stated, “With an overall response rate of 99% and 100% tumor control, DOORwaY90 demonstrates that personalized dosimetry with SIR-Spheres can produce results that challenge conventional approaches and broaden what is possible in liver-directed therapy for patients with unresectable HCC.”

SIR-Spheres® resin microspheres represent the only FDA-approved radioembolization therapy in the U.S. for treating unresectable liver cancer stemming from metastatic colorectal cancer (mCRC) and HCC.

Conclusion

In conclusion, these findings from the DOORwaY90 study not only reinforce the efficacy of SIR-Spheres® in cancer treatment but also pave the way for more innovative approaches in managing complex cases of HCC. As Sirtex Medical continues to lead advancements in interventional oncology, it empowers both physicians and patients with effective, minimally invasive cancer treatment options.

For detailed information regarding SIR-Spheres and guidance on integrating personalized dosimetry into clinical practice, interested parties can reach out to Sirtex at [email protected].

About Sirtex Medical

Sirtex Medical is a global healthcare company dedicated to advancing minimally invasive embolization and cancer treatment solutions. The company has operations spanning the United States, Australia, Europe, and Asia, providing innovative interventional oncology solutions to healthcare providers and patients globally. For more insights, visit www.sirtex.com.